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Abstract: This paper introduces the burden of cervical cancer and the primary and secondary 
preventative interventions currently available, and provides an overview of the bivalent and 
quadrivalent human papillomavirus (HPV) vaccines. A brief account of the virology and 
the clinical efficacy of both is given. Examinations of the two main types of cost analyses, 
cost-effective and cost-benefit, as well as examples, are presented in addition to the possible 
impact these analyses and further economic models will have on budget and policy making 
decisions. In general, most cost analyses provide support for the implementation of primary 
prevention strategies, HPV immunization, in conjunction with cervical cancer screening programs. 
Vaccination against HPV, therefore, is a cost-effective cervical cancer prevention mechanism.
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Introduction
Cervical cancer is the second most common cause of cancer death in adult females. 
In developing nations where the barriers to access of are the highest, it is frequently 
the most common cancer in women because these areas tend to be underserved and 
resource-poor.1,2 Cervical cancer incidence and mortality rates vary globally, a function 
of ethnicity, demography, geography, socioeconomic status, and access to healthcare. 
In the United States (US) and many other industrialized nations, because of the 
increased screening, cervical cancer incidence and mortality rates have been declining 
for decades.3 Yet even in developed countries, 1 out of 125 women (0 to 64 years) still 
have an accumulated lifetime risk of acquiring the disease.4 Despite notably reduced 
incidence and mortality rates, the burden of cervical cancer precursor lesions and the 
disease is substantial to both social and health care paradigms.
The human papillomavirus (HPV) is the only recognized carcinogen that is a 
“necessary cause” of cancer in humans.5,6 It is sexually transmitted and high-risk types 
of HPV have been linked to cancers of the cervix, penis, vulva, vagina, anal canal, and 
perianal skin.5,7 Without intervention or treatment, most HPV infections will clear the 
body naturally. However, should persistent infection of HPV occur, the risk for cervical 
and other HPV-associated cancers increases.6 In the US alone, HPV types 16 and 18 
result in approximately 30% of vaginal and vulvar cancers, 70% of cervical cancer, 
and 80% of anal cancer.8–12 More than 90% of anogenital warts in the US are attribut-
able to HPV types 6 and 11.12,13 The total direct and indirect economic costs associated 
with HPV-related genital warts as well as screening for and treating cervical cancer in 
the United States could be as much as US$4 billion each year.8,14,15 Eliminating these 
burdens necessitates inexpensive, efficient, and effective interventions.ClinicoEconomics and Outcomes Research 2009:1 18
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Cervical cancer accounts for approximately 10% of 
all cancers, not including non-melanoma skin cancers. It 
is a leading cause of morbidity and mortality afflicting 
women and is preventable.20 In 2006, the FDA approved a 
quadrivalent HPV vaccine (Gardasil®; Merck & Co. Inc., 
White House Station, NJ, USA). This vaccine targets the 
high-risk types of the virus that are the most significant 
contributors to cervical cancer, types 16 and 18, which cause 
approximately 70% of all cervical cancer cases, and the two 
low-risk types most associated with genital warts, types 6 
and 11.16,21 A second prophylactic vaccine (Cervarix®; Glaxo-
SmithKline Biologicals, Rixensart, Belgium) is bivalent and 
targets HPV types 16 and 18. Licensed for use in Europe 
but awaiting approval from the Food and Drug Administra-
tion in the US, the bivalent vaccine still shows promise as 
an immunization and an opportunity for preventative care 
against cervical cancer.
Early detection, diagnosis, and treatment of cervical 
cancer prelesions and neoplasia, is the most important fac-
tor in designing and implementing cervical cancer screening 
programs.18 With the advent of quadrivalent and bivalent 
prophylactic vaccines that target the two high-risk types of 
HPV, types 16 and 18, that can cause cervical cancer should 
persistent infection occur, there is new hope for a primary 
prevention strategy coupled with pre-existing screening 
programs, to eradicate cervical cancer and other diseases 
associated with HPV and to alleviate the financial burden.
This review will examine management and cost 
effectiveness strategies presently employed in cervical 
cancer prevention including primary and secondary inter-
ventions. Elucidation of the effects of these interventions 
on cost analyses, budget impacting, and modeling as well as 
implications to healthcare and public health policy will serve 
to provide information on the methods that will be the most 
successful in the quest to reduce cervical cancer incidence 
and mortality in the future.
Primary and secondary prevention 
interventions
The implementation of screening programs is the secondary 
prevention strategy instrumental in reducing cervical 
cancer incidence and mortality rates in the 20th century. 
In unscreened populations alone, introduction of screening 
programs has demonstrated significant reductions in cervi-
cal cancer rates by 60% to 90% within 3 years of screening 
instigation.19 In conjunction with the Pap smear and other 
technological advancements such as liquid-based cytology, 
HPV DNA testing, and computer-assisted smear-reading, 
some countries have seen drastic reductions in cervical cancer 
mortality rates by as much as 75% since these tactics were 
introduced over 50 years ago.20,21 Secondary prevention has 
thus played a pivotal role in diminishing cervical cancer 
mortality rates.
Traditionally, cervical cancer screening programs 
have utilized cervical cytology as a means of detecting 
and diagnosing cervical cancer and precancerous lesions. 
Despite these interventions, cervical cancer incidence and 
mortality rates and the economic burden affiliated with this 
disease, remain high. In developing nations and rural areas of 
industrialized countries where barriers to access of care are 
evident, this may be due to implementation and compliance 
issues of cervical cancer screening programs.9,22 Developing 
cervical cancer screening programs requires consideration of 
many issues and parameters. These include the age interval 
at which screening should occur and new technological 
advancements that enhance and can combine with existing 
methods of cytology.22,23
Cervical cancer is preventable because the progression 
from preneoplasia to invasive cancer is gradual, which affords 
ample time for detection and treatment. Furthermore, it is 
preventable because the methodology and strategy, namely 
repetitive screening and Pap Smears, needed to detect cervical 
premalignancy are available. Cervical cytology, however, is 
not without imperfections. Approximately 30% of all cervical 
cancers result from subpar sensitivity.24 Moreover, cytologic 
screening has less than optimal sensitivity, equivocal results, 
and restrained reproducibility.1,25,26 As a result, noncytology-
based screening programs are evolving that employ HPV 
DNA testing or visual inspection with acetic acid followed by 
treatment using cryotherapy. These alternatives are cheaper 
than cytology and are equally as reliable. In resource-poor 
areas where colposcopy and histopathological services are 
not readily available, these options are attractive.28 In addi-
tion, HPV DNA testing shows greater sensitivity, as much as 
90%, in many screening trials, and may therefore be a more 
optimal secondary prevention method.29
Screening alone is not sufficient to maximize cervical 
cancer prevention. The HPV vaccination is a primary pre-
vention strategy that mandates investigation and possible 
incorporation into existing secondary screening programs. 
The American Cancer Society has stipulated guidelines for 
the use of the HPV vaccine as a preventative method, recom-
mending that public health and policy endeavors guarantee 
access to and promote the prophylaxis. More importantly, 
efforts should encourage, through education, all females 
of every racial, ethnic, and socioeconomic group of the ClinicoEconomics and Outcomes Research 2009:1 19
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appropriate age to receive the vaccination, especially those 
females most affected by the burden of cervical cancer.5
Overview of vaccines, virology,  
and clinical efficacy
Most HPV infections generally educe local cellular immunity 
and clear the body naturally. However, research suggests that 
the response elicited by antibodies produced by natural HPV 
infection may be limited in the body although they seem to 
protect against repeat infection of the same type of HPV. 
The two prophylactic vaccines commercially available that 
target HPV and utilize L1 structural capsular proteins may 
confer longer lasting immunity. The proteins derive from 
genetic recombination of Saccharomyces cervisiae, in the 
case of the quadrivalent vaccine, or baculovirus, in the case 
of the bivalent vaccine, and resemble real HPV antigeni-
cally in their ability to form virus-like particles (VLPs) and 
self-assemble.2,29 A strong, persistent, type-specific response 
follows vaccination of HPV VLPs, which do not comprise 
attenuated or live virus.2,30,31
Both vaccines are highly efficacious. Three studies, a 
phase II study among females aged 16 to 23 years of age 
and two phase III studies, one among females aged 16 to 
23 years and the other females aged 16 to 26 years, have been 
conducted that evaluate the efficacy of the quadrivalent HPV 
vaccine.32–34 From these studies, the determined efficacy of the 
quadrivalent vaccine was extremely high against persistent 
infection by HPV types 6, 11, 16, and 18, against low-grade 
cervical intraepithelial neoplasia (CIN) and adenocarcinoma 
in situ. Additional studies have indicated that after 3 years, 
the quadrivalent vaccine specifically has an 86% efficacy 
in combating type 16 infection (P  0.0001), 89% efficacy 
against type 18 (P = 0.0103), and an 89% efficacy for the 
prevention of persistent cervical infection of all four types 
(P  0.0001).32,35
The efficacy of the bivalent HPV vaccine needs further 
elucidation. Fewer studies have examined the efficacy of this 
vaccine most likely because it is younger and does not have 
worldwide recognition and licensure. The published litera-
ture, however, indicates that the bivalent vaccine is highly 
efficacious against persistent infection by HPV types 16 and 
18. Phase II and phase III trials of the bivalent vaccine demon-
strated efficacious success in preventing high-grade CIN and 
cervical cancer that were causally associated to HPV types 16 
and 18 in addition to preventing persistent infection of the two 
types.36,37 Another study found the bivalent vaccine to have 
100% (95% CI, 42.4% to 100%) efficacy in preventing CIN 
related to HPV types 16 and 18 among women 15 to 25 years 
of age that completed the 3-dose vaccination regimen and 
participated in a follow-up study for 44 to 53 months.38
It remains unknown whether boosters will be necessary in 
the future for persistent immunity or long-term efficacy and 
it will be years before the ascertainment of the definitiveness 
of the vaccine in preventing cervical cancer later in life. 
Nevertheless, the vaccine shows unprecedented promise in 
combating cervical cancer by eliminating persistent HPV 
infection.17
Comparative review of cost analyses
The costs of treating cervical cancer are not likely to remain 
constant especially in countries where the population is aging 
and the life expectancy is increasing with accompanying risks 
of cancer and other chronic diseases.3,39 Positive indirect 
costs such as time and travel costs should reasonably rise 
as well as the costs to treat cervical precancer and invasive 
cervical cancer side effects.3,40 Since detection and diagnoses 
of cervical diseases occurs at different stages of cancer, an 
exact monetary value of treating cervical cancer is impossible 
to quantify. Treatment options and costs are a function of 
the cancer stage, and costs rise as the severity of diagnosis 
increases and can vary by age.3,41 Cost analyses, therefore, 
attempt to discern the effects of implementing cervical cancer 
prevention programs that incorporate a primary prevention 
mechanism, the HPV vaccine, on the costs associated with 
cervical cancer and its sequela.
Most economic evaluations conducted and relevant to 
the study of the HPV vaccine are cost-effectiveness analy-
ses and not cost-benefit analyses.42–44 Despite the fact that 
both are instruments used to judge the efficiency of health 
services programs, there is a substantial difference between 
the two types of analyses. While both are important for 
decision-making in planning, implementing, continuing, and 
expanding health service programs and both analyses assist in 
identification and comparability of either known or expected 
costs with actual or anticipated benefits, the primary differ-
ence is in the manner of expression of the outcomes or effects 
of a program. Cost-benefit analyses attribute monetary value 
to both costs and benefits, which at times can be difficult to 
assess. Cost-effectiveness analyses, on the other hand, only 
monetize the costs of a program and not the benefits. Benefits 
in a cost-effectiveness analysis, usually expressed as program 
outcomes, represent the goals of the program. Therefore, in 
relation to health services programs, cost-benefit analyses 
are primarily concerned with cost relative to output, while 
cost-effectiveness analyses assess goal achievement and 
program efficiency.45ClinicoEconomics and Outcomes Research 2009:1 20
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It is important to note that neither cost-benefit analysis 
nor cost-effectiveness analysis is necessarily better. The 
cost-effectiveness analyses that have been conducted on 
potential HPV vaccine programs and existing cervical cancer 
screening programs all support use of the vaccine because 
of increased efficiency in these programs. However, these 
analyses are not necessarily generalizable to all cervical 
cancer-screening programs across the US and the rest of the 
world. Demographics affect the reliability of these analyses 
since varying populations can lead very different lifestyles. 
A cost-benefit analysis, therefore, could result in dramatically 
different conclusions for a specific region of study than these 
cost-effectiveness evaluations.
There is a plethora of proposed mathematical models 
for predicting both the economic and epidemiological 
impact of the HPV vaccine against HPV infection and 
cervical cancer.44 The three prominent types of math-
ematical models are cohort, population dynamic, and 
hybrid. The various model types all exploit common 
factors that affect the risk associated with acquiring and 
clearing infection of HPV, progression of CIN and sub-
sequent regression, and incidence of invasive cancer. For 
example, the probability of acquiring HPV in simulation 
model of one cohort depends on present age, age of sexual 
debut, the type of HPV, exposure to screening and Pap 
smears, and whether immunity has been conferred to the 
specific type of HPV acquired. On the other hand, sexual 
contact patterns and viral distribution influence rates of 
HPV acquisition in transmission models.2 All the models 
in this area, regardless of type, however, conclude that 
vaccination against HPV in the end can reduce incidence 
and mortality of cervical cancer, but the models evaluate 
the cost-effectiveness of preventative vaccination strategies 
rather than the cost-benefit of the vaccine itself.6,43
It is not possible to calculate the cost of quality-adjusted 
life years (QALY) and disability-adjusted life years (DALY) 
without concretely defining the quantity of indirect costs, 
which is a necessary component of the calculation. How-
ever, a recently published report summarized four previous 
studies that estimated the potential cost-effectiveness of 
the HPV vaccine in regards to screening practices in the 
US. Two studies employed Markov models of the natural 
history of HPV infection to estimate the cost-effectiveness 
of vaccinating 12-year-old females. These studies, under 
different assumptions of vaccine efficacy and cost, estimated 
lifetime reductions in cervical cancer incidence in the 
vaccinated cohort between 20% and 58%. The corresponding 
costs of vaccination compared to no vaccination ranged from 
US$22,800 per QALY, in 2001 dollars, to $24,300 per QALY 
in 2002 dollars.23,42 The two remaining analyses based on 
dynamic transmission models found reductions of 62% and 
75% and costs of US$14,600 per QALY in 2001 dollars and 
US$3,000 per QALY in 2005 dollars respectively.46,47
Few cost-benefit analyses on the HPV vaccine are avail-
able. One cost-benefit analysis performed on Medicaid-
enrolled females of the Appalachian region of Kentucky in 
the US found that utilizing the HPV vaccine as a primary 
route for prevention is indeed a cost-saving strategy when the 
rising cost of healthcare, aging population, and costs to treat 
cervical cancer are taken into account. The female popula-
tion of the Appalachian region of Kentucky is underserved 
and particularly vulnerable to developing cervical cancer 
and dying from it due to a number of risk factors including 
poverty, lower education levels, barriers to health insurance 
and access to care, and higher smoking rates.48 The analysis 
found that though actual cost savings recognition would 
not occur for several decades as the vaccinated population 
ages, implementing a prevention plan for cervical cancer that 
includes annual HPV vaccination of Medicaid-enrolled ado-
lescent females is not only beneficial to the public’s health, 
but also a cost-efficient strategy to the Medicaid system.3
Mathematical models are a valuable asset because they 
can mimic the natural history of disease and provide informa-
tion that integrates both clinical and economical data. This 
information is useful in policy decision-making as well as 
budget determinations in addition to estimating potential 
cost-effectiveness of multiple strategies. Since the HPV 
vaccine has been determined to be a cost-effective primary 
prevention strategy, care is necessary in formulating pro-
gram budgets, especially in the initial years of vaccination, 
when the costs to vaccinate against HPV and treat cervical 
cancer are still high. Recognition of cost-savings will not 
occur immediately. Should implementation of immuniza-
tion programs occur, it would not be until the population of 
vaccinated adolescent females aged 12 to 25 reach at least 
the median age for diagnosis of cervical cancer, which was 
48 years during the 2000 to 2004 period.
The costs to treat cervical cancer cases in nonvaccinated 
females and the costs to maintain screening programs would 
still incur. However, consideration of the fact that the HPV 
vaccine will also decrease incidence of anogenital warts and 
other associated HPV diseases in addition to thwarting the 
need for diagnosis, treatment, and surgical intervention of 
these ailments is important to acknowledge and may offset 
additional costs. While only monetary costs are considered 
here, the HPV vaccine should decrease quality-of-life costs ClinicoEconomics and Outcomes Research 2009:1 21
Management of cervical cancer prevention Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
in all females who receive the vaccine. Though vaccinating 
against HPV may indeed be a cost-effective strategy, the 
realization of this effectiveness would not occur for another 
25 to 30 years postimmunization program initiation, and con-
sideration of these total direct and indirect costs attributable to 
vaccination and treatment of cervical cancer is necessary.49
Implication for healthcare policy
Healthcare costs are growing rapidly and the economic 
impact of HPV and cervical cancer is substantial.50 Expendi-
tures of an estimated US$4 billion occur in the US on direct 
costs associated with HPV, its sequela, and cervical cancer. 
Each year, almost US$200 million is ascribable to managing 
anogenital warts, US$300 to US$400 million on invasive 
cervical cancer, and the residual funds on routine cervical 
cancer screening, follow-up of abnormal Pap tests, and cer-
vical intraepithelial neoplasia.15,51 It is therefore imperative 
to streamline cervical cancer screening programs to make 
them more effective and efficient especially in the current 
ailing global economy.
Since the debut of the HPV vaccine, global acceptance 
has been slow for numerous reasons including the lack of 
awareness of HPV and its link to cervical cancer.52 Increas-
ing public knowledge is critical as well as garnering support 
from physicians whose recommendations are substantial in 
influencing parents to get their children vaccinated if not 
mandated to do so.53 Despite the fact that the efficacy of 
both the quadrivalent and bivalent vaccines and demon-
strated cost-effectiveness, other issues such as challenges 
in delivering the vaccine prevent worldwide recognition and 
acceptance of the HPV vaccine as well. One study found that 
reluctance to immunize depends on certain characteristics of 
the vaccine including cost and safety, insurance coverage, 
and the potential impact of the vaccine on adolescent female 
sexual activity.54 Dispelling misconceptions regarding the 
vaccine with education about the vaccine will support global 
attainment of maximal immunization coverage against HPV 
and increase invasive cervical cancer aversion.
Research indicates that the HPV vaccine will be beneficial 
in reducing the high-risk types of HPV infection, which 
account for 59% of total HPV infections and cause cervical 
cancer, as well as two of the low-risk types that are associated 
with genital warts in the US.42 Despite the fact that the vaccine 
is highly efficacious, most studies recommend retention of 
screening as a method for early detection. Instead, studies 
suggest delaying the age of onset of Pap screening until the 
mid-thirties for vaccinated individuals, since the vaccine pre-
vents the primary types of HPV infections that are associated 
with cervical cancer and manifest in younger sexually active 
adolescents. This ensures that the practice is more efficient 
and less costly.55 In addition, recent research supports decreas-
ing the frequency at which screening occurs in vaccinated 
females from annually to approximately every 3 years. This 
would further increase the cost-effectiveness of cervical can-
cer screening programs that require screening of large num-
bers of women in order to prevent one death when a majority 
of women (80%) with high-grade cervical intraepithelial 
neoplasia do not progress to invasive cancer.55,56
A number of barriers exist for the women of low-income, 
resource poor communities. Barriers to optimal screening, 
diagnosis, and treatment of cervical cancer, including pov-
erty, geographic isolation, isolation due to age, illiteracy, 
culture, fear, acceptability by healthcare providers, and lack 
of availability of community care.48 These barriers could 
similarly affect the number of women that receive the HPV 
vaccine. The vaccine, administered in a three-part process, 
requires at least three separate visits to a healthcare provider. 
These barriers, combined with the fact that generally fewer 
healthcare providers are available in impoverished areas that 
practice preventive medicine rather than treat acute condi-
tions, can be a significant deterrent to women who may have 
to travel long distances to see a provider. Receiving educa-
tion about HPV, cervical cancer, and the vaccine itself may 
depend on its availability, accessibility, and acceptability 
and could have a significant impact.
Public health efforts and policy should focus on 
maximizing HPV vaccine coverage by making it affordable 
and accessible to all women and educating the public on the 
benefits of the HPV vaccines. At present, legislature in the US 
and around the world has sought to install mandatory require-
ments for girls of middle school entrance age to receive 
the vaccine in order to minimize HPV rates and increase 
population immunity. Moreover, actualization of the largest 
scale of herd immunity against HPV would occur should the 
vaccine gain licensure and promotion for use in males.
Conclusions
The effects of the HPV vaccine, aside from prevention 
of persistent HPV infection, on cervical cancer are 
unascertainable at present. Administration of vaccination 
against HPV is recommended in young females age 
12 to 25, though the vaccine is safe for use among females 
aged 9 through 26.57 The cost of the three vaccine series, 
approximately US$360, is the most expensive vaccine avail-
able to date. It poses a major barrier of access to many women 
including those most likely to benefit from the vaccine: ClinicoEconomics and Outcomes Research 2009:1 22
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females from low-income communities and communities 
of color.58 Despite the fact that public financing may be 
obtainable to those who qualify and the availability of the 
quadrivalent vaccine through a vaccine assistance program 
to some females that are uninsured, many do not meet these 
criteria or have insurance coverage by companies that do 
not pay for the immunization. These females may not have 
access to the vaccine because of its significant expense.59 
Furthermore, neither is known of the longevity of immunity 
conferred by the vaccine nor the need for booster shots in the 
future to maintain immunity. If titers are necessary, the costs 
associated with vaccination against HPV will rise.42 Regard-
less, most studies maintain that administration of the vaccine 
should occur in females around the 12th year of life.60
The predicted increase of quality-adjusted life expectancy 
for females of this age is 2.8 days or 4.0 quality-adjusted 
life-days. The vaccine, it is further hypothesized, will avert 
more than 224,255 cases of HPV infection, 112,710 cases 
of squamous intraepithelial lesions, 3317 cases of cervical 
cancer, and 1340 deaths caused by cervical cancer over the 
life span of the present US cohort of 12-year-old females. 
Moreover, in order to avert or prevent one case of cervical 
cancer, 600 girls would require vaccination.42
Cost-related studies reinforce the importance of such 
economic analyses in determining resource allocation, 
especially in public health, and further support evidence-based 
decision-making when considering public health interventions 
and other prevention programs. Further research should 
reevaluate cervical cancer screening recommendations, 
vaccine administration, and program implementation. Addi-
tional investigation of the duration of protection from both 
the bivalent and quadrivalent vaccines, virologic surveil-
lance, and the safety of the HPV vaccines should continue 
in the future. Monitoring HPV-related outcomes and explor-
ing the possibility of vaccinating against HPV at the same 
time as other adolescent vaccines is of significant value. 
Consideration of male immunization and herd immunity will 
also affect future public health policy.
Disclosures
The author has no conflicts of interest to declare.
References
  1.  Foerster V, Murtagh J. Vaccines for prevention of human papillomavirus 
infection. Issues in emerging health technologies, Issue 75. Ottawa: 
Canadian Coordinating Office for Health Technology Assessment; 
2005.
  2.  Saslow D, Castle P, Cox JT, et al. American Cancer Society Guideline 
for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical 
Cancer and Its Precursors. CA Cancer J Clin. 2007;57(1):7–28.
  3.  Prasad S, Hill R. A Cost-Benefit Analysis on the HPV Vaccine in 
Medicaid-Enrolled Females of the Applachian Region of Kentucky. 
KMA. 2008;106:271–276.
  4.  Torné A, Alonso I, Puig-Tintoré, Pahisa J. Clinical role of cervical 
cancer vaccination: When and whom to vaccinate? Gynecol Oncol. 
2008;110:S15–S16.
  5.  Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal 
relation between human Papillomavirus and cervical cancer. J Clin 
Pathol. 2002;55:244–265.
  6.  Dasbach EJ, Elbasha EH, Insinga RP. Mathematical Models for 
Predicting the Epidemiologic and Economic Impact of Vaccination 
against Human Papillomavirus Infection and Disease. Epidemiol Rev. 
2006;28:88–100.
  7.  Moscicki A. Epidemiology and oncogenesis of human papillomavirus 
(HPV) infection. In Human Papillomavirus Vaccines: Future Role of 
the Pediatrician in Preventing Cervical Cancer. New York, NY: The 
Academy for Healthcare Education; 2005. p. 1–3.
  8.  Chesson HW, Ekwueme DU, Saraiya M, Markowitz L. Cost-effectiveness 
of human papillomavirus vaccination in the United States. Emerg Infect 
Dis. 2008;14:244–251.
  9.  Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. 
Vaccine. 2006;24(Suppl 3):S11–S25.
10.  Centers for Disease Control and Prevention. Quadrivalent human 
Papillomavirus vaccine: recommendation of the Advisory Committee 
on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56 
(RR-2):1–24.
11.  Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV 
type distribution in high-grade cervical lesions and cervical cancer: a 
meta-analysis. Br J Cancer. 2003;89:101–105.
12.  Dunne EF, Markowitz LE. Genital human papillomavirus infection. 
Clin Infect Dis. 2006;43:624–629.
13.  Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus 
(HPV) type distribution and serological response to HPV type 6 
virus-like particles in patients with genital wars. J Clin Microbiol. 
1995;33:2058–2063.
14. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The esti-
mated direct medical cost of sexually transmitted diseases among 
American youth, 2000. Perspect Sex Reprod Health. 2004;36: 
11–19.
15.  Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic 
burden of preventing and treating anogenital human papillomavirus-
related disease in the US: analytic framework and review of the literature. 
PharmacoEconomics. 2005;23:1107–1122.
16.  Franco E, Harper D. Vaccination against human Papillomavirus 
infection: a new paradigm in cervical cancer control. Vaccine. 
2005;23:2388–2394.
17.  Blatter MM. HPV Vaccine Efficacy and Tolerability. In Human 
Papillomavirus Vaccines: Future Role of the Pediatrician in Prevent-
ing Cervical Cancer. New York, NY: The Academy for Healthcare 
Education; 2005. p. 6–7.
18.  Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society 
guideline for the early detection of cervical neoplasia and cancer. CA 
Cancer J Clin. 2002;52:342–362.
19.  International Agency for Research on Cancer (IARC). Handbooks of 
Cancer Prevention: Cervix Cancer Screening. Lyon, France: IARC; 
2005.
20.  Devesa SS. Descriptive epidemiology of cancer of the uterine cervix. 
Obstet Gyencol. 1984;63:605–612.
21.  Ries L, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 
1975–2003: National Cancer Institute. Bethesda, MD: National Cancer 
Institute; 2006.
22.  Rogoza RM, Ferko N, Bentley J, et al. Optimization of primary and 
secondary cervical cancer prevention strategies in an era of cervical 
cancer vaccination: A multi-regional health economic analysis. Vaccine. 
2008;26S:F46–F58.
23.  Goldie SJ, Kim JJ, Myers E. Chapter 19: cost-effectiveness of cervical 
cancer screening. Vaccine. 2006;24(S3):164–170.ClinicoEconomics and Outcomes Research 2009:1
ClinicoEconomics and Outcomes Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journal
ClinicoEconomics & Outcomes Research is an international, peer-
reviewed open-access journal focusing on Health Technology Assess-
ment, Pharmacoeconomics and Outcomes Research in the areas of 
diagnosis, medical devices, and clinical, surgical and pharmacological 
intervention. The economic impact of health policy and health systems 
organization also constitute important areas of coverage. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
23
Management of cervical cancer prevention Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
24.  Sawaya GF, Washing AE. Cervical cancer screening: which techniques 
should be used and why? Clin Obstet Gynecol. 1999;42:922–938.
25.  Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou 
test in screening for and follow-up of cervical cytologic abnormalities: 
a systemic review. Ann Intern Med. 2000;132:810–819.
26.  Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined 
Significance-Low grade Squamous Intraepithelial Lesion Triage Study 
(ALTS) Group. Interobserver reproducibility of cervical cytologic and 
histologic interpretations: realistic estimates from the ASCUS-LSIL 
Triage Study. JAMA. 2001;285:1500–1505.
27.  Denny L, Kuhn L, De Souza M, Pollack A, Dupree W, Wright T. Screen-
and-Treat Approaches for Cervical Cancer Prevention in Low-Resource 
Settings: A Randomized Controlled Trial. JAMA. 2005;294:2173–2181.
28.  Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 
consensus guidelines for the management of women with cervical 
cytological abnormalities. JAMA. 2002;287:2120–2129.
29.  Bayas J, Costas L, Muñoz A. Cervical cancer vaccination indications, 
efficacy, and side effects. Gynecol Oncol. 2008;110:S11–S14.
30.  Pinto LA, Edwards J, Castle PE, et al. Cellular immune responses 
to human papillomavirus (HPV)-16 L1 in healthy volunteers immu-
nized with recombinant HPV-16 L1virus-like particles. J Infect Dis. 
2003;188:327–338.
31.  Emeny RT, Wheeler CM, Jansen KU, et al. Priming of human papil-
lomavirus type 11-specific humoral and cellular immune responses 
in college-aged women with a virus-like particle vaccine. J Virol. 
2002;76:7832–7842.
32.  Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human 
papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine 
in young women: a randomized double-blind placebo-controlled mul-
ticentre phase II efficacy trial. Lancet Oncol. 2005;6:271–278.
33.  Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses 
following administration of a vaccine targeting human papillomavirus 
Types 6, 11, 16, 18. Vaccine. 2006;24:5571–5583.
34.  Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a 
prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1-
virus like particle vaccine through 5 years of follow-up. Br J Cancer. 
2006;95:1459–1466.
35.  Blatter MM. HPV Vaccine Efficacy and Tolerability. In Human 
Papillomavirus Vaccines: Future Role of the Pediatrician in Preventing 
Cervical Cancer. New York, NY: The Academy for Healthcare 
Education; 2005. p. 6–7.
36.  Keam S, Harper D. Human Papillomavirus Types 16 and 18 Vaccine 
(Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix™]. Drugs. 
2008;68:359–372.
37.  GlaxoSmithKline. GSK submits Cervarix™ license application to 
Japan’s health authorities [media release]. 2007 Sept 28.
38.  Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 
4.5 years of a bivalent L1 virus-like particle vaccine against human 
papillomavirus types 16 and 18: follow-up from a randomized control 
trial. Lancet. 2006;367:1247–1255.
39.  Bouchardy C, Rapiti E, Blagojevic S, Vlastos A, Vlastos G. Older 
Female Cancer Patients: Importance, Causes, and Consequences of 
Undertreatment. J Clin Oncol. 2005;25:1858–1869.
40.  Brownson R, Baker E, Leet T, Gillespie K. Evidence-Based Public 
Health. Oxford University Press, Inc: New York, New York; 2005.
41.  Insigna R, Glass A, Rush B. The health care costs of cervical human 
papillomavirus-related disease. Am J Obste Gynecol. 2004;191:114–120.
42.  Sanders GD, Taira AV. Cost Effectiveness of a Potential Vaccine for 
Human Papillomavirus. Emerg Infect Dis. 2003;9:37–48.
43.  Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathemati-
cal model for the natural history of human papillomavirus infection and 
cervical carcinogenesis. Am J Epidemiol. 2000;151:1158–1171.
44.  Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting 
the epidemiologic and economic impact of vaccination against human 
papillomavirus infection and disease. Epidemiol Rev. 2006;28:88–100.
45.  Shi L. Health Services Research Methods. Albany, NY: Delmar 
Thompson Learning; 1997.
46.  Taira AV, Neukermans CP, Sanders GD. Evaluating human papilloma-
virus vaccination programs. Emerg Infect Dis. 2004;10:1915–1923.
47.  Elbasha E, Dasbach EJ, Insinga RP. Model for assessing human papil-
lomavirus vaccination. Emerg Infect Dis. 2007;13:29–41.
48.  Friedell G, Linville L, Hullet S. Cancer control in rural Appalachia. 
In Cancer Supplement, 6th Biennial Symposium on Minorities, the 
Medically Underserved and Cancer. 1998;83:1868–1871.
49.  Surveillance Epidemiology and End Results (SEER) [homepage on the 
Internet]. Cancer Stat Fact Sheets: Cancer of the Cervix Uteri. [cited 
2003 Feb 13]. Available from: http://seer.cancer.gov/statfacts/html/
cervix_print.html
50.  Bodenheimer T. High and Rising Health Care Costs. Part 1: Seeking 
an Explanation. Ann Internal Med. 2005;42:847–854.
51.  Chesson JM, Blandford TL, Gift GT, Irwin KL. The Estimated Direct 
Medical Cost of Sexually Transmitted Diseases Among American 
Youth, 2000. Perspect Sex Reprod Health. 2004;36:11–19.
52.  Tiro J, Meissner H, Kobrin S, et al. What Do US Women Know About 
HPV and Cervical Cancer? Cancer Epidemiol Biomarkers Prev. 
2007;16:288–294.
53.  Zimet G. Improving Adolescent Health: Focus on HPV Vaccine Accep-
tance. J Adolesc Health. 2005;37:S17–S23.
54.  Ishibashi K, Koopmans J, Curlin F, Alexander K, Ross L. Paediatri-
cians’ attitudes and practices towards HPV vaccination. Acta Paediatric. 
2008;97:1550–1556.
55.  Kulasingam SL, Myers ER. Potential Health and Economic Impact 
of Adding a Human Papillomavirus Vaccine to Screening Programs. 
JAMA. 2003;290:781–789.
56.  Raffle AE, Alden BA, Quinn M, Babb PJ, Brett MT. Outcomes of 
screening to prevent cancer: analysis of cumulative incidence of cervical 
abnormality and modeling of cases and deaths prevented. Br Med J. 
2003;326:901–905.
57.  Centers for Disease Control and Prevention (CDC). Recommended 
Immunization Schedules for Persons Aged 0–18 Years – United States, 
2007. MMWR. 2007;55:Q1–Q4
58.  Dailard C. Achieving Universal Vaccination Against Cervical Cancer 
In the United States: The Need and the Means. Guttmacher Policy 
Review. 2006;9:12– 6.
59.  Merck Vaccine Patient Assistance Program. Merck and Co., Inc. 2008. 
Available at: http://www.merck.com/merckhelps/vaccines/home.html. 
Accessed April 30, 2009.
60.  Dunne EF, Unger ER, Sternberg M, McQuillan et al. Prevalence 
of HPV Infection Among Females in the United States. JAMA. 
2007;297:813–819.